K. Rasmussen

发表

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.

W W Offen, A. Levey, S. Gauthier, 1997, Archives of neurology.

Intracellular studies in the facial nucleus illustrating a simple new method for obtaining viable motoneurons in adult rat brain slices

G. Aghajanian, K. Rasmussen, G K Aghajanian, 1989, Synapse.

N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a Novel Metabotropic Glutamate 2 Potentiator with Potential Anxiolytic/Antidepressant Properties: In Vivo Profiling Suggests a Link between Behavioral and Central Nervous System Neu

G. Marek, K. Perry, J. Witkin, 2011, Journal of Pharmacology and Experimental Therapeutics.

The Opioid Crisis and the Future of Addiction and Pain Therapeutics

M. Hall, G. Sittampalam, N. Coussens, 2019, The Journal of Pharmacology and Experimental Therapeutics.

Individual recognition of female hamsters by males: Role of chemical cues and of the olfactory and vomeronasal systems

R. Johnston, K. Rasmussen, 1984, Physiology & Behavior.

Xanomeline, an M1/M4 preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice

F. Bymaster, A. Fink-Jensen, Michael D B Swedberg, 2000, Schizophrenia Research.

Typical and Atypical Antipsychotic Drugs Increase Extracellular Histamine Levels in the Rat Medial Prefrontal Cortex: Contribution of Histamine H1 Receptor Blockade

K. Perry, D. Nelson, K. Svensson, 2012, Front. Psychiatry.

Preclinical Pharmacology of FMPD [6-Fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: A Potential Novel Antipsychotic with Lower Histamine H1 Receptor Affinity Than Olanzapine

Todd R. Wiernicki, F. Bymaster, L. Nisenbaum, 2005, Journal of Pharmacology and Experimental Therapeutics.

The novel 5-Hydroxytryptamine(1A) antagonist LY426965: effects on nicotine withdrawal and interactions with fluoxetine.

D. Wong, T. Branchek, J. Zgombick, 2000, The Journal of pharmacology and experimental therapeutics.

Nicotine withdrawal leads to increased firing rates of midbrain dopamine neurons

K. Rasmussen, J. F. Czachura, Janet F. Czachura, 1995, Neuroreport.

Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice.

F. Bymaster, A. Fink-Jensen, Michael D B Swedberg, 2000, Schizophrenia research.

The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms.

L. Thompson, S. Hemrick-Luecke, K. Rasmussen, 2006, Schizophrenia bulletin.

The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits

S. Mitchell, J. Witkin, D. Schoepp, 2016, The Journal of Pharmacology and Experimental Therapeutics.

The mGlu5 receptor antagonists MPEP and MTEP attenuate behavioral signs of morphine withdrawal and morphine-withdrawal-induced activation of locus coeruleus neurons in rats

M. Seager, K. Rasmussen, J. Berger, 2005, Neuropharmacology.

Nicotine withdrawal leads to increased sensitivity of serotonergic neurons to the 5-HT1A agonist 8-OH-DPAT

K. Rasmussen, J. F. Czachura, 1997, Psychopharmacology.

Moxonidine, a selective imidazoline-1 receptor agonist, suppresses the effects of ethanol withdrawal on the acoustic startle response in rats

K. Rasmussen, M. Kallman, Jim L. Vandergriff, 2000, Biological Psychiatry.

The 5-HT3 receptor antagonist zatosetron decreases the number of spontaneously active A10 dopamine neurons.

K. Rasmussen, J. F. Czachura, M. Stockton, 1991, European journal of pharmacology.

Serotonin‐1A antagonists attenuate the effects of nicotine withdrawal on the auditory startle response

K. Rasmussen, M. Kallman, D. Helton, 1997, Synapse.

Phenethylamine hallucinogens in the locus coeruleus: potency of action correlates with rank order of 5-HT2 binding affinity.

G. Aghajanian, R. Glennon, K. Rasmussen, 1986, European journal of pharmacology.

In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug.

D. Wong, F. Bymaster, D. Nelson, 1997, The Journal of clinical psychiatry.

Electrophysiological effects of diphenylpyrazolidinone cholecystokinin-B and cholecystokinin-A antagonists on midbrain dopamine neurons.

J. Howbert, K. Rasmussen, J. F. Czachura, 1993, The Journal of pharmacology and experimental therapeutics.

Olanzapine, a novel atypical antipsychotic, has electrophysiological effects on A9 and A10 dopamine cells similar to clozapine

K. Rasmussen, M. Stockton, 1995, Schizophrenia Research.

Creating more effective antidepressants: clues from the clinic.

K. Rasmussen, 2006, Drug discovery today.

Section Review—Central & Peripheral Nervous Systems: Therapeutic Potential of Cholecystokinin-B Antagonists

K. Rasmussen, 1995 .

Quinazolinone cholecystokinin (CCK)‐B antagonists decrease midbrain dopamine unit activity

K. Rasmussen, J. F. Czachura, M. Yu, 1994, Synapse.

The Orexin-1 Receptor Antagonist SB-334867 Blocks the Effects of Antipsychotics on the Activity of A9 and A10 Dopamine Neurons: Implications for Antipsychotic Therapy

K. Rasmussen, Yili Yang, M. Hsu, 2007, Neuropsychopharmacology.

Effect of hallucinogens on spontaneous and sensory-evoked locus coeruleus unit activity in the rat: reversal by selective 5-HT2antagonists

G. Aghajanian, K. Rasmussen, 1986, Brain Research.

Morphine Withdrawal as a State of Glutamate Hyperactivity: The Effects of Glutamate Receptor Subtype Ligands on Morphine-Withdrawal Symptoms

K. Rasmussen, 2002 .

Morphine Withdrawal as a State of Glutamate Hyperactivity

K. Rasmussen, 2002 .

The selective mGlu2/3 receptor agonist LY354740 attenuates morphine-withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal

K. Rasmussen, Jim L. Vandergriff, 1999, Neuropharmacology.

A Selective AMPA Antagonist, LY293558, Suppresses Morphine Withdrawal-Induced Activation of Locus Coeruleus Neurons and Behavioral Signs of Morphine Withdrawal

G. Aghajanian, J. Kogan, K. Rasmussen, 1996, Neuropsychopharmacology.

NMDA receptor antagonists suppress behaviors but not norepinephrine turnover or locus coeruleus unit activity induced by opiate withdrawal.

K. Perry, P. Ornstein, R. Fuller, 1991, European journal of pharmacology.

Afferent effects on locus coeruleus in opiate withdrawal.

K. Rasmussen, 1991, Progress in brain research.

Single unit activity of locus coeruleus neurons in the freely moving cat I. During naturalistic behaviors and in response to simple and complex stimuli

B. Jacobs, D. Morilak, K. Rasmussen, 1986, Brain Research.

Chapter 1. Recent Progress in Serotonin (5-HT)1A Receptor Modulators

K. Rasmussen, V. P. Rocco, 1995 .

The CCK-B antagonist LY288513 blocks effects of diazepam withdrawal on auditory startle.

K. Rasmussen, D. Helton, J. Berger, 1993, Neuroreport.

Forebrain-selective AMPA-receptor antagonism guided by TARP γ-8 as an antiepileptic mechanism

J. Isaac, D. Bredt, E. Nisenbaum, 2016, Nature Medicine.

Single unit activity of locus coeruleus neurons in the freely moving cat II. Conditioning and pharmacologic studies

B. Jacobs, K. Rasmussen, 1986, Brain Research.

Potential role of muscarinic receptors in schizophrenia.

F. Bymaster, A. Fink-Jensen, Michael D B Swedberg, 1999, Life sciences.

Effects of short-term and chronic olanzapine treatment on immediate early gene protein and tyrosine hydroxylase immunoreactivity in the rat locus coeruleus and medial prefrontal cortex

G. Dawe, K. Rasmussen, V. Verma, 2006, Neuroscience.

Opiate withdrawal and the rat locus coeruleus: behavioral, electrophysiological, and biochemical correlates

G. Aghajanian, G. Aghajanian, E. Nestler, 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

The Role of the Locus Coeruleus and N-Methyl-D-Aspartic Acid (NMDA) and AMPA Receptors in Opiate Withdrawal

K. Rasmussen, 1995, Neuropsychopharmacology.

Activation of midbrain presumed dopaminergic neurones by muscarinic cholinergic receptors: an in vivo electrophysiological study in the rat

K. Rasmussen, B. Gronier, 1998, British journal of pharmacology.

Failure to block responses of locus coeruleus neurons to somatosensory stimuli by destruction of two major afferent nuclei

G. Aghajanian, K. Rasmussen, 1989, Synapse.

Psychological Stress Activates the Inflammasome via Release of Adenosine Triphosphate and Stimulation of the Purinergic Type 2X7 Receptor

Nanxin Li, M. Banasr, R. Duman, 2016, Biological Psychiatry.

High-Fat Diet Induced Anxiety and Anhedonia: Impact on Brain Homeostasis and Inflammation

R. Duman, K. T. Ota, K. Rasmussen, 2016, Neuropsychopharmacology.

Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane .

F. Bymaster, A. Fink-Jensen, Michael D B Swedberg, 1998, European journal of pharmacology.

Evaluation of 5-HT7 receptor antagonism for the treatment of anxiety, depression, and schizophrenia through the use of receptor-deficient mice

M. Seager, G. Nomikos, Xia Li, 2019, Behavioural Brain Research.

Olanzapine: a basic science update

D. Wong, K. Perry, F. Bymaster, 1999, British Journal of Psychiatry.

Electrophysiological Effects of Olanzapine, a Novel Atypical Antipsychotic, on A9 and A10 Dopamine Neurons

K. Rasmussen, M. Stockton, 1996, Neuropsychopharmacology.

Olanzapine, a novel atypical antipsychotic, reversesd-amphetamine-induced inhibition of midbrain dopamine cells

K. Rasmussen, M. Stockton, 1996, Psychopharmacology.

The novel atypical antipsychotic olanzapine, but not the CCK-B antagonist LY288513, blocks apomorphine-induced disruption of pre-pulse inhibition

K. Rasmussen, M. Gates, J. F. Czachura, 1997, Neuroscience Letters.

Some behavioral effects of hallucinogens are mediated by a postsynaptic serotonergic action: evidence from single unit studies in freely moving cats.

B. Jacobs, J. Heym, K. Rasmussen, 1984, European journal of pharmacology.

The selective mGlu2/3 receptor antagonist LY341495 exacerbates behavioral signs of morphine withdrawal and morphine-withdrawal-induced activation of locus coeruleus neurons

K. Rasmussen, Jim L. Vandergriff, M. Hsu, 2004, Neuropharmacology.

Withdrawal-induced activation of locus coeruleus neurons in opiate-dependent rats: attenuation by lesions of the nucleus paragigantocellularis

G. Aghajanian, K. Rasmussen, 1989, Brain Research.

Preclinical Evaluation of Melanin-Concentrating Hormone Receptor 1 Antagonism for the Treatment of Obesity and Depression

Xia Li, J. Witkin, Yanyun Chen, 2009, Journal of Pharmacology and Experimental Therapeutics.

Olanzapine activates the rat locus coeruleus: in vivo electrophysiology and c-Fos immunoreactivity

T. Sharp, M. O'Neill, G. Dawe, 2001, Biological Psychiatry.

Pertussis toxin treatment differentially affects cholinergic and dopaminergic receptor stimulation of midbrain dopaminergic neurons

K. Rasmussen, B. Gronier, 1999, Neuropharmacology.

Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive N-Methyl-d-Aspartate Receptor Antagonist in Rodents: Evidence Supporting the Use of mGlu2/3 Antagonists, for the Treatment of Depression.

P. Ornstein, V. Tolstikov, S. Mitchell, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Phosphodiesterase-1b (Pde1b) knockout mice are resistant to forced swim and tail suspension induced immobility and show upregulation of Pde10a

C. Vorhees, R. Duman, J. R. Hufgard, 2017, Psychopharmacology.

NIDA’s medication development priorities in response to the Opioid Crisis: ten most wanted

K. Rasmussen, J. Acri, D. A. White, 2018, Neuropsychopharmacology.

Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder

M. Seager, V. Barth, L. Phebus, 2005, Psychopharmacology.

Fluoxetine administration potentiates the effect of olanzapine on locus coeruleus neuronal activity

M. Seager, V. Barth, L. Phebus, 2004, Biological Psychiatry.

NMDA antagonists and clonidine block c‐fos expression during morphine withdrawal

K. Rasmussen, C. Inturrisi, M. Brodsky, 1995, Synapse.

The selective iGluR1-4 (AMPA) antagonist LY300168 attenuates morphine-withdrawal-induced activation of locus coeruleus neurons and behavioural signs of morphine withdrawal

K. Rasmussen, Jim L. Vandergriff, 2003, Neuropharmacology.

AMPA antagonist LY293558 blocks the development, without blocking the expression, of behavioral sensitization to morphine

W. Carlezon, K. Rasmussen, Eric J. Nestler, 1999, Synapse.

Age-dependent dysregulation of locus coeruleus firing in a transgenic rat model of Alzheimer's disease

J. Weiss, D. Weinshenker, Seth D. Depuy, 2022, Neurobiology of Aging.

Evidence that central 5‐HT2A and 5‐HT2B/C receptors regulate 5‐HT cell firing in the dorsal raphe nucleus of the anaesthetised rat

T. Sharp, K. Rasmussen, K. Allers, 2003 .

Evidence that central 5‐HT2A and 5‐HT2B/C receptors regulate 5‐HT cell firing in the dorsal raphe nucleus of the anaesthetised rat

T. Sharp, K. Rasmussen, K. Allers, 2003, British journal of pharmacology.

Electrophysiology of the Central Serotonin System: Receptor Subtypes and Transducer Mechanisms a

G. Aghajanian, G. Aghajanian, K. Rasmussen, 1990, Annals of the New York Academy of Sciences.

Excitatory amino acids and morphine withdrawal: differential effects of central and peripheral kynurenic acid administration

G. Aghajanian, J. Krystal, K. Rasmussen, 2005, Psychopharmacology.

Nimodipine reduction of naltrexone-precipitated locus coeruleus activation and abstinence behavior in morphine-dependent rats

J. Krystal, E. Nestler, K. Rasmussen, 1996, Physiology & Behavior.

Central nervous system characterization of the new cholecystokininB antagonist LY288513

K. Rasmussen, M. Kallman, D. Helton, 1996, Pharmacology Biochemistry and Behavior.

Locus coeruleus unit activity in freely moving cats is increased following systemic morphine administration

B. Jacobs, K. Rasmussen, 1985, Brain Research.

Coordinate Regulation of the Cyclic AMP System with Firing Rate and Expression of Tyrosine Hydroxylase in the Rat Locus Coeruleus: Effects of Chronic Stress and Drug Treatments

E. Nestler, J. Haycock, R. Duman, 1992, Journal of neurochemistry.

Effects of acute and chronic administration of fluoxetine on the activity of serotonergic neurons in the dorsal raphe nucleus of the rat

K. Rasmussen, Kurt Rasmussen, Janet F. Czachura, 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.

Electrophysiology of Central Serotonin Receptor Subtypes

G. Aghajanian, K. Rasmussen, J. Sprouse, 1988 .

Activation of the mesocorticolimbic dopaminergic system by stimulation of muscarinic cholinergic receptors in the ventral tegmental area

K. Perry, K. Rasmussen, B. Gronier, 2000, Psychopharmacology.

Single unit response of noradrenergic, serotonergic and dopaminergic neurons in freely moving cats to simple sensory stimuli

Barry L. Jacobs, B. Jacobs, R. Strecker, 1986, Brain Research.

Attenuation of the effects of fluoxetine on serotonergic neuronal activity by pindolol in rats

K. Rasmussen, E. Shanks, A. McCreary, 2004, Neuroscience Letters.

Inhibition of A9 and A10 dopamine cells by the cholecystokinin‐B antagonist LY262691: Mediation through feedback pathways from forebrain sites

J. Howbert, K. Rasmussen, M. Stockton, 1993, Synapse.

Cholecystokinin (CCK) and schizophrenia: the selective CCKB antagonist LY262691 decreases midbrain dopamine unit activity.

J. Howbert, K. Rasmussen, J. F. Czachura, 1991, European journal of pharmacology.

Potency of antipsychotics in reversing the effects of a hallucinogenic drug on locus coeruleus neurons correlates with 5-HT2 binding affinity.

G. Aghajanian, K. Rasmussen, 1988, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

Activity of serotonin-containing neurons in nucleus centralis superior of freely moving cats

B. Jacobs, J. Heym, K. Rasmussen, 1984, Experimental Neurology.

Serotonin excitation of facial motoneurons: Receptor subtype characterization

G. Aghajanian, K. Rasmussen, 1990, Synapse.

CCK, Schizophrenia, and Anxiety

K. Rasmussen, 1994, Annals of the New York Academy of Sciences.

Electrophysiology of Brain Serotonin Receptors: Subtype Specificity for Effector Mechanisms

G. Aghajanian, K. Rasmussen, J. Sprouse, 1990 .

P. Ornstein, S. Mitchell, G. Gilmour, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Comparative Effects of LY3020371, a Potent and Selective mGlu2/3 Receptor Antagonist, and Ketamine, a Non-Competitive NMDA Receptor Antagonist in Rodents: Evidence Supporting the Use of mGlu2/3 Antagonists for the Treatment of Depression

V. Tolstikov, S. Mitchell, G. Gilmour, 2017 .

Psychological Stress Activates the Inflammasome via Release of Adenosine Triphosphate and Stimulation of the Purinergic Type 2X7 Receptor

Nanxin Li, M. Banasr, R. Duman, 2016, Biological Psychiatry.

Translating Pharmacology into Therapeutics to Fight the Opioid Crisis

G. Marek, K. Cunningham, K. Rasmussen, 2019, The Journal of Pharmacology and Experimental Therapeutics.

Pharmacological characterization of LY293284: A 5-HT1A receptor agonist with high potency and selectivity.

R. Fuller, D. Nelson, K. Rasmussen, 1994, The Journal of pharmacology and experimental therapeutics.

Nicotine withdrawal: a behavioral assessment using schedule controlled responding, locomotor activity, and sensorimotor reactivity

K. Rasmussen, J. Tizzano, D. Helton, 2005, Psychopharmacology.